0918 GMT - Roche posted a solid first quarter, exceeding sales expectations and reaffirming its annual guidance despite the Trump administration tariff concerns, Barclays analysts say in a note. The Swiss pharma company's blockbuster drugs for multiple sclerosis Ocrevus and eye treatment Vabysmo missed Barclays' and market consensus, the analysts say. Investors will focus on diagnostics sales, hampered by pricing reforms in China, and Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues, they say. Shares fall 0.4% to 257.10 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 05:18 ET (09:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.